BROOKS vs TORNTPHARM: Stock Comparison
BROOKS LAB is the larger company by market capitalisation. BROOKS LAB shows a lower P/E, lower leverage and a higher net margin, while TORRENT PHARMACEUTICALS L shows a higher ROE, a higher dividend yield and faster revenue growth. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.
Metric snapshot
BROOKS leads 6; TORNTPHARM leads 7 of 13
Interactive comparison
Compare the numbers that shape the decision
Every row uses its own scale. Switch lenses to compare like with like.
Valuation lens
What price are you paying?
✓ marks the usual favourable reading; it is not a recommendation.
Key Differences
Each difference is a single, relative reading — StockeZee does not name an overall winner.
Profile
| Metric | BROOKS | TORNTPHARM |
|---|---|---|
| Sector | Healthcare | Healthcare |
| Industry | Pharmaceuticals | Pharmaceuticals |
Price
| Metric | BROOKS | TORNTPHARM |
|---|---|---|
| Live Price | ₹69.46 | ₹4,617.1 |
| Day Change | 18.17% | -2.1% |
| Volume | 15.09 L | 2.54 L |
| 52-Week High | ₹131.9 | ₹5,250 |
| 52-Week Low | ₹36.3 | ₹3,480.6 |
| Distance from 52W High | -47.34% | -12.06% |
Valuation
| Metric | BROOKS | TORNTPHARM |
|---|---|---|
| Market Cap | ₹20,461 L Cr | ₹1.78 L Cr |
| P/E Ratio | 8.22x | 72.55x |
| P/B Ratio | 1.65x | 18.86x |
| EPS | ₹4.49 | ₹14.54 |
| Book Value | ₹41.64 | ₹519.58 |
| Dividend Yield | 0% | 0.8% |
Growth
| Metric | BROOKS | TORNTPHARM |
|---|---|---|
| Revenue Growth (TTM YoY) | -6.37% | 41.8% |
| EPS Growth (TTM YoY) | 0% | -21.7% |
| Qtr Sales Growth | 0% | -15.5% |
| Qtr Profit Growth | -225.96% | -13.07% |
Profitability & Leverage
| Metric | BROOKS | TORNTPHARM |
|---|---|---|
| ROE | 20.04% | 25.93% |
| ROCE | 5.38% | 11.33% |
| Net Margin | 28.67% | 15.73% |
| Operating Margin | 7.74% | 30.23% |
| Debt to Equity | 0.06x | 1.68x |
Shareholding
As of Jun 2026 • change vs previous quarter| Metric | BROOKS | TORNTPHARM |
|---|---|---|
| Promoter Holding | 52.62% | 60.78%▼ 7.53 pp |
| FII Holding | 0%▼ 0.17 pp | 17.97%▲ 2.53 pp |
| DII Holding | 10.38% | 12.87%▲ 3.04 pp |
| Public Holding | 37%▲ 0.16 pp | 8.38%▲ 1.96 pp |
How to Read This Comparison
Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.
Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: BROOKS LAB and TORRENT PHARMACEUTICALS L.
Related Comparisons
Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.